November 10, 2021

AmerisourceBergen to Now Offer Prime Therapeutics’ IntegratedRx – Oncology to Eligible Hospital, Health System & Oncology Practice Customers

Conshohocken, Pa. (November 10, 2021) – AmerisourceBergen, a global healthcare company and a leader in supporting specialty pharmaceuticals through distribution, commercialization, and provider access and solutions, today announced that it is now offering Prime Therapeutics’ IntegratedRxTM – Oncology program to eligible hospital, health system and independent oncology practice customers. Prime Therapeutics (Prime) is a pharmacy benefit manager (PBM) serving more than 33 million members. Through medically-integrated networks of independent oncology practices or hospitals and health systems, IntegratedRx - Oncology promotes lower costs, quicker time-to-medication, better adherence and an improved patient and provider experience for Blue Plans and their members.

Prime’s IntegratedRx – Oncology streamlines the treatment pathway for oncology patients by allowing them to receive their oncolytic and companion medications directly from their oncologist or affiliated hospital pharmacy. Contracting and claims adjudication support will be made possible through AmerisourceBergen’s Pharmacy Services Administrative Organizations (PSAOs), including the nation’s first-ever specialty-focused PSAO, Accelerate Specialty Network.

“Many of today’s payer and reimbursement models restrict physicians and health systems’ abilities to holistically manage patients and directly dispense medications at the site of care,” said Matt Wolf, RPh, Senior Vice President of Provider Solutions at AmerisourceBergen. “Prime’s IntegratedRx™ - Oncology program changes the game by enabling providers to dispense patients’ oncology and companion medications in the clinical setting, improving therapy management and the patient experience. We are proud to be in on the ground level of IntegratedRx™ – Oncology, and we look forward to making this model available to our customers.” 

Participation in this program through AmerisourceBergen is contingent upon PSAO enrollment, Specialty Oncology Network (SON) participation (for medically-integrated dispensing practices), and data sharing capabilities, which will allow for demonstration of improved patient care. These integrated networks enable the patient to receive their medications from their provider versus a central-fill pharmacy. The program is currently limited to oral oncolytic therapies and companion medicines. In order to participate, Prime requires medically-integrated dispensing practices to have, or seek within one year’s time, accreditation from one of three recognized accrediting bodies, ACHCURAC or NCODA. Health systems must receive accreditation from ACHC, The Joint Commission or URAC.

“AmerisourceBergen has been an unwavering supporter of patient choice and flexibility and making cancer treatment accessible at the community level,” said Lisa Harrison, RPh, President of Specialty Distribution at AmerisourceBergen. “By participating in this program, our customers have the opportunity to showcase the value of a truly integrated oncology delivery model. This new model will create expanded commercial access to oral oncolytics, enhanced clinical oversight of cancer patients, and will lead to increased administrative efficiencies for providers. We are excited to see how this program shapes the next chapter of cancer care in the U.S, and we hope to be able to expand this offering to other specialty practices in the future.”  

For more information, please visit: https://www.amerisourcebergen.com/provider-solutions/operational-and-financial-performance/integratedrx

 

About AmerisourceBergen
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies, and providers, we create unparalleled access, efficiency, and reliability for human and animal health. Our 41,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at amerisourcebergen.com